ReviewHypertension research : official journal of the Japanese Society of Hypertension2022
Role of the microbiota in hypertension and antihypertensive drug metabolism.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 45 citations in OpenAlex.
- Prospective association between the gut microbiome and incident hypertension: a 20-year cohort study.Journal of hypertension · 2026Article
- Gut Microbiota and Hypertension: Mechanisms, Drug Interactions, and Translational Directions for Individualized Therapy.International journal of general medicine · 2026Review
- Reframing glucolipid metabolic disorders through the lens of the oral microbiome: from pathophysiological mechanisms to translational potential.Frontiers in nutrition · 2026Review
- Food as Medicine for Hypertension: Microbiota as Mediators.Hypertension (Dallas, Tex. : 1979) · 2025Review
- Drugs Versus Microbiota: How Pharmacotherapy Affects Gut and Probiotic Bacteria.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Early-Life Prevention of Cardiovascular-Kidney-Metabolic Syndrome: The DOHaD Perspective on Resveratrol and Short-Chain Fatty Acids.Antioxidants (Basel, Switzerland) · 2025Review
- The Gut Health Revolution: Herbs and Dietary Phytochemicals in Balancing Gut Microbiota for Optimal Human Health.Current pharmaceutical biotechnology · 2025Review
- Dietary polyphenols maintain human health through modulation of gut microbiota.Frontiers in pharmacology · 2025Review
- Effects of gut microbiota dysbiosis on the metabolism and pharmacokinetics of losartan in rats: from endogenous to ceftriaxone-induced dysbiosis.Frontiers in microbiology · 2025Article
- Gut microbiota and arterial hypertension: a narrative review.Archives of medical science : AMS · 2025Article
- Differential effects of electroacupuncture and manual acupuncture on spontaneously hypertensive rats: insights from intestinal microbiota and metabolomics.Frontiers in molecular biosciences · 2025Article
- Knowledge domains and hotspots of the association between hypertension and noise: a bibliometric analysis and visualization study from 2003 to 2023.Frontiers in cardiovascular medicine · 2025Article
- Salt-Responsive Gut Microbiota Induces Sex-Specific Blood Pressure Changes.Circulation research · 2024Article
- Non/Low-Caloric Artificial Sweeteners and Gut Microbiome: From Perturbed Species to Mechanisms.Metabolites · 2024Review
- Gut bacteria-derived extracellular vesicles and hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Constipation and high blood pressure variability.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Relationship between defecation status and blood pressure level or blood pressure variability.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Higher Short-Chain Fermentable Carbohydrates Are Associated with Lower Body Fat and Higher Insulin Sensitivity in People with Prediabetes.Nutrients · 2023Article
- Genetically engineered Lactobacillus paracasei rescues colonic angiotensin converting enzyme 2 (ACE2) and attenuates hypertension in female Ace2 knock out rats.Pharmacological research · 2023Article
- Effect of Gut Microbiota on the Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that the gut microbiota plays an important role in the development and pathogenesis of hypertension. Dysbiosis, an imbalance in the composition and function of the gut microbiota, was shown to be associated with hypertension in both animal models and humans. In this review, we provide insights into host-microbiota interactions and summarize the evidence supporting the importance of the microbiota in blood pressure (BP) regulation. Metabolites produced by the gut microbiota, especially short-chain fatty acids (SCFAs), modulate BP and vascular responses. Harmful gut-derived metabolites, such as trimethylamine N-oxide and several uremic toxins, exert proatherosclerotic, prothrombotic, and proinflammatory effects. High-salt intake alters the composition of the microbiota, and this microbial alteration contributes to the pathogenesis of salt-sensitive hypertension. In addition, the microbiota may impact the metabolism of drugs and steroid hormones in the host. The drug-metabolizing activities of the microbiota affect the pharmacokinetic parameters of antihypertensive drugs and contribute to the pathogenesis of licorice-induced pseudohyperaldosteronism. Furthermore, the oral microbiota plays a role in BP regulation by producing nitric oxide, which lowers BP via its vasodilatory effects. Thus, antihypertensive intervention strategies targeting the microbiota, such as the use of prebiotics, probiotics, and postbiotics (e.g., SCFAs), are considered new therapeutic options for the treatment of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.